FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:166-175 July 20, 1995 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Renal osteodystrophy, the term used to describe the skeletal complications of end-stage renal disease, is a multifactorial disorder of bone remodeling. The actions of some of the factors involved are well defined, and successful strategies have been designed to prevent them. For example, the identification of secondary hyperparathyroidism and 1,25-dihydroxycholecalciferol (1,25-dihydroxyvitamin D₃) deficiency as major contributors to renal osteodystrophy has led to the development of treatment regimens that can maintain normal serum calcium and phosphate concentrations, reduce parathyroid hormone secretion, and correct a deficiency of 1,25-dihydroxycholecalciferol. These improvements in treatment have resulted in decreases in the . . . [Full Text of this Article]

Normal Bone Remodeling

Pathophysiology

Osteitis Fibrosa

Osteomalacia

Adynamic Bone Disease

Diagnosis

Current Management Recommendations

Control of Serum Phosphate

Control of Serum Calcium

Use of Vitamin D Analogues

Conclusions

Source Information

From the Renal Division, Departments of Medicine (K.A.H.) and Pathology (S.L.T.), Jewish Hospital at Washington University Medical Center, St. Louis.

Address reprint requests to Dr. Hruska at the Renal Division, Jewish Hospital, 216 S. Kingshighway Blvd., St. Louis, MO 63110.

References

Related Letters:

Renal Osteodystrophy
Barzel U. S., Hruska K. A.
Extract | Full Text  
N Engl J Med 1995; 333:1428, Nov 23, 1995. Correspondence

This article has been cited by other articles:

• Courtney, A E, Maxwell, A P (2009). Chronic kidney disease and bisphosphonate treatment: are prescribing guidelines unnecessarily restrictive?. Postgrad. Med. J. 85: 327-330 [Abstract] [Full Text]  
• Belozeroff, V., Goodman, W. G., Ren, L., Kalantar-Zadeh, K. (2009). Cinacalcet Lowers Serum Alkaline Phosphatase in Maintenance Hemodialysis Patients. CJASN 4: 673-679 [Abstract] [Full Text]  
• Ouzouni, S., Kouidi, E., Sioulis, A., Grekas, D., Deligiannis, A. (2009). Effects of intradialytic exercise training on health-related quality of life indices in haemodialysis patients. Clin Rehabil 23: 53-63 [Abstract]  
• Toussaint, N. D., Lau, K. K., Strauss, B. J., Polkinghorne, K. R., Kerr, P. G. (2009). Determination and Validation of Aortic Calcification Measurement from Lateral Bone Densitometry in Dialysis Patients. CJASN 4: 119-127 [Abstract] [Full Text]  
• Toussaint, N. D., Elder, G. J., Kerr, P. G. (2009). Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue. CJASN 4: 221-233 [Abstract] [Full Text]  
• Shinaberger, C. S, Greenland, S., Kopple, J. D, Van Wyck, D., Mehrotra, R., Kovesdy, C. P, Kalantar-Zadeh, K. (2008). Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. Am. J. Clin. Nutr. 88: 1511-1518 [Abstract] [Full Text]  
• Miller, P. D. (2008). The Role of Bone Biopsy in Patients with Chronic Renal Failure. CJASN 3: S140-S150 [Abstract] [Full Text]  
• Ott, S. M. (2008). Histomorphometric Measurements of Bone Turnover, Mineralization, and Volume. CJASN 3: S151-S156 [Abstract] [Full Text]  
• Gal-Moscovici, A., Sprague, S. M. (2008). Role of Bone Biopsy in Stages 3 to 4 Chronic Kidney Disease. CJASN 3: S170-S174 [Abstract] [Full Text]  
• Mathew, S., Lund, R. J., Chaudhary, L. R., Geurs, T., Hruska, K. A. (2008). Vitamin D Receptor Activators Can Protect against Vascular Calcification. J. Am. Soc. Nephrol. 19: 1509-1519 [Abstract] [Full Text]  
• Messa, P., Macario, F., Yaqoob, M., Bouman, K., Braun, J., von Albertini, B., Brink, H., Maduell, F., Graf, H., Frazao, J. M., Bos, W. J., Torregrosa, V., Saha, H., Reichel, H., Wilkie, M., Zani, V. J., Molemans, B., Carter, D., Locatelli, F. (2008). The OPTIMA Study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism. CJASN 3: 36-45 [Abstract] [Full Text]  
• Saab, G., Whaley-Connell, A. T., Khanna, R., Sowers, J. R. (2007). Review: Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification. Ther Adv Cardiovasc Dis 1: 107-112 [Abstract]  
• Lin, B.-R., Chang, C.-C., Chen, L.-R., Wu, M.-H., Wang, M.-Y., Kuo, I-H., Chu, C.-Y., Chang, K.-J., Lee, P.-H., Chen, W.-J., Kuo, M.-L., Lin, M.-T. (2007). Cysteine-Rich 61 (CCN1) Enhances Chemotactic Migration, Transendothelial Cell Migration, and Intravasation by Concomitantly Up-Regulating Chemokine Receptor 1 and 2. Mol Cancer Res 5: 1111-1123 [Abstract] [Full Text]  
• Rudser, K. D., de Boer, I. H., Dooley, A., Young, B., Kestenbaum, B. (2007). Fracture Risk after Parathyroidectomy among Chronic Hemodialysis Patients. J. Am. Soc. Nephrol. 18: 2401-2407 [Abstract] [Full Text]  
• Hollander, J. M., Mechanick, J. I. (2006). Nutrition Support and the Chronic Critical Illness Syndrome. Nutr Clin Pract 21: 587-604 [Abstract] [Full Text]  
• Westenfeld, R., Ketteler, M., Brandenburg, V. M. (2006). Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density. Nephrol Dial Transplant 21: 2075-2077 [Full Text]  
• Chertow, G. M., Blumenthal, S., Turner, S., Roppolo, M., Stern, L., Chi, E. M., Reed, J., on behalf of the CONTROL Investigators, (2006). Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium x Phosphate. CJASN 1: 305-312 [Abstract] [Full Text]  
• Kaczirek, K., Prager, G., Riss, P., Wunderer, G., Asari, R., Scheuba, C., Bieglmayer, C., Niederle, B. (2006). Novel parathyroid hormone (1-84) assay as basis for parathyroid hormone monitoring in renal hyperparathyroidism.. Arch Surg 141: 129-134 [Abstract] [Full Text]  
• Schucker, J. J., Ward, K. E. (2005). Hyperphosphatemia and phosphate binders. Am J Health Syst Pharm 62: 2355-2361 [Abstract] [Full Text]  
• Freundlich, M., Alonzo, E., Bellorin-Font, E., Weisinger, J. R. (2005). Increased Osteoblastic Activity and Expression of Receptor Activator of NF-{kappa}B Ligand in Nonuremic Nephrotic Syndrome. J. Am. Soc. Nephrol. 16: 2198-2204 [Abstract] [Full Text]  
• Lien, Y.-H. H., Silva, A. L., Whittman, D. (2005). Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 20: 1232-1237 [Abstract] [Full Text]  
• Nanovic, L. (2005). Electrolytes and Fluid Management in Hemodialysis and Peritoneal Dialysis. Nutr Clin Pract 20: 192-201 [Abstract] [Full Text]  
• Maalouf, N. M., Shane, E. (2005). Osteoporosis after Solid Organ Transplantation. J. Clin. Endocrinol. Metab. 90: 2456-2465 [Abstract] [Full Text]  
• Davies, M. R., Lund, Richard. J., Mathew, S., Hruska, K. A. (2005). Low Turnover Osteodystrophy and Vascular Calcification Are Amenable to Skeletal Anabolism in an Animal Model of Chronic Kidney Disease and the Metabolic Syndrome. J. Am. Soc. Nephrol. 16: 917-928 [Abstract] [Full Text]  
• Rodriguez, M., Nemeth, E., Martin, D. (2005). The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am. J. Physiol. Renal Physiol. 288: F253-F264 [Abstract] [Full Text]  
• Steddon, S. J., McIntyre, C. W., Schroeder, N. J., Burrin, J. M., Cunningham, J. (2004). Impaired release of interleukin-6 from human osteoblastic cells in the uraemic milieu. Nephrol Dial Transplant 19: 3078-3083 [Abstract] [Full Text]  
• Joy, M. S, Kshirsagar, A. V, Franceschini, N. (2004). Calcimimetics and the Treatment of Primary and Secondary Hyperparathyroidism. The Annals of Pharmacotherapy 38: 1871-1880 [Abstract] [Full Text]  
• Block, G. A., Martin, K. J., de Francisco, A. L.M., Turner, S. A., Avram, M. M., Suranyi, M. G., Hercz, G., Cunningham, J., Abu-Alfa, A. K., Messa, P., Coyne, D. W., Locatelli, F., Cohen, R. M., Evenepoel, P., Moe, S. M., Fournier, A., Braun, J., McCary, L. C., Zani, V. J., Olson, K. A., Drueke, T. B., Goodman, W. G. (2004). Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. NEJM 350: 1516-1525 [Abstract] [Full Text]  
• Brewer, A. J., Canaff, L., Hendy, G. N., Tenenhouse, H. S. (2004). Differential regulation of PHEX expression in bone and parathyroid gland by chronic renal insufficiency and 1,25-dihydroxyvitamin D3. Am. J. Physiol. Renal Physiol. 286: F739-F748 [Abstract] [Full Text]  
• Lund, R. J., Davies, M. R., Brown, A. J., Hruska, K. A. (2004). Successful Treatment of an Adynamic Bone Disorder with Bone Morphogenetic Protein-7 in a Renal Ablation Model. J. Am. Soc. Nephrol. 15: 359-369 [Abstract] [Full Text]  
• Fukagawa, M., Nakanishi, S. (2003). Role of parathyroid intervention in the management of secondary hyperparathyroidism. Nephrol Dial Transplant 18: iii23-26 [Abstract] [Full Text]  
• Kitaoka, M., Onoda, N., Kitamura, H., Koiwa, F., Tanaka, M., Fukagawa, M. (2003). Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. Nephrol Dial Transplant 18: iii38-41 [Abstract] [Full Text]  
• Nakanishi, S., Yano, S., Nomura, R., Tsukamoto, T., Shimizu, Y., Shin, J., Fukagawa, M. (2003). Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 18: iii47-49 [Abstract] [Full Text]  
• Hudson, J. Q. (2002). Improved Strategies for the Treatment of Renal Osteodystrophy. Journal of Pharmacy Practice 15: 456-471 [Abstract]  
• Collins, W. O., Buchman, C. A. (2002). Radiology Quiz Case 2. Arch Otolaryngol Head Neck Surg 128: 457-460 [Full Text]  
• SALUSKY, I. B., GOODMAN, W. G. (2001). Adynamic Renal Osteodystrophy: Is There a Problem?. J. Am. Soc. Nephrol. 12: 1978-1985 [Full Text]  
• MONIER-FAUGERE, M.-C., MAWAD, H., QI, Q., FRIEDLER, R. M., MALLUCHE, H. H. (2000). High Prevalence of Low Bone Turnover and Occurrence of Osteomalacia after Kidney Transplantation. J. Am. Soc. Nephrol. 11: 1093-1099 [Abstract] [Full Text]  
• GUPTA, A., KALLENBACH, L. R., ZASUWA, G., DIVINE, G. W. (2000). Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients. J. Am. Soc. Nephrol. 11: 330-334 [Abstract] [Full Text]  
• Fukagawa, M., Kitaoka, M., Tominaga, Y., Akizawa, T., Kurokawa, K. (1999). Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid in chronic dialysis patientsthe Japanese strategy. Nephrol Dial Transplant 14: 2574-2577 [Full Text]  
• Murayama, A., Takeyama, K.-i., Kitanaka, S., Kodera, Y., Kawaguchi, Y., Hosoya, T., Kato, S. (1999). Positive and Negative Regulations of the Renal 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase Gene by Parathyroid Hormone, Calcitonin, and 1{alpha},25(OH)2D3 in Intact Animals. Endocrinology 140: 2224-2231 [Abstract] [Full Text]  
• Duan, Y., De Luca, V., Seeman, E. (1999). Parathyroid Hormone Deficiency and Excess: Similar Effects on Trabecular Bone But Differing Effects on Cortical Bone. J. Clin. Endocrinol. Metab. 84: 718-722 [Abstract] [Full Text]  
• Rahman, M., Smith, M. C. (1998). Chronic Renal Insufficiency: A Diagnostic and Therapeutic Approach. Arch Intern Med 158: 1743-1752 [Abstract] [Full Text]  
• Barzel, U. S., Hruska, K. A. (1995). Renal Osteodystrophy. NEJM 333: 1428-1428 [Full Text]